Can quabodepistat be safely combined with levetiracetam, and what dosing and monitoring considerations apply?

Insufficient Evidence for Quabodepistat and Levetiracetam Combination

I cannot provide a recommendation regarding the combination of quabodepistat and levetiracetam because the provided evidence contains no information about quabodepistat interacting with levetiracetam or any antiseizure medications. The evidence base consists primarily of tuberculosis treatment guidelines from 2003 and levetiracetam pharmacology data, with only one recent study on quabodepistat 1.

What We Know About Each Drug Individually

Quabodepistat

• Novel tuberculosis drug currently in clinical development 1
• Studied in combination with delamanid and/or bedaquiline for drug-susceptible pulmonary tuberculosis
• The 2025 study showed it was safe and well-tolerated when combined with other TB medications over 14 days 1
• No published data exists on interactions with antiseizure medications

Levetiracetam

• Well-characterized antiseizure medication with favorable pharmacokinetic profile 2
• Minimal drug-drug interactions compared to older antiepileptic drugs 3
• Primarily renally cleared; dose adjustment required in renal impairment 2
• Common adverse effects: somnolence, asthenia, dizziness, infection 2
• Starting dose: 500 mg twice daily; goal dose: 1000-2000 mg daily in divided doses 4

Critical Knowledge Gaps

There is no published literature addressing:

• Pharmacokinetic interactions between quabodepistat and levetiracetam
• Safety data for this specific combination
• Whether quabodepistat affects hepatic enzymes that might alter levetiracetam metabolism
• Whether levetiracetam affects the efficacy or safety of tuberculosis treatment

Clinical Approach When Evidence Is Absent

If you must use both medications simultaneously:

Baseline Assessment:

• Document baseline neurological status and seizure frequency
• Obtain baseline complete blood count (levetiracetam can cause CNS depression) 4
• Check renal function (both drugs have renal considerations) 2

Monitoring Strategy:

• Weekly clinical assessment during the first month
• Monitor for additive CNS effects (somnolence, dizziness, confusion)
• Consider levetiracetam therapeutic drug monitoring if seizure control changes 5, 6
• Watch for unexpected adverse effects suggesting an interaction

Dose Considerations:

• Start levetiracetam at standard doses (500 mg BID) unless renal impairment present 2
• Titrate slowly (increase by 500 mg daily every 2 weeks) to minimize CNS side effects 4
• Adjust levetiracetam for creatinine clearance <70 mL/min 2

Red Flags Requiring Immediate Evaluation:

• Unexplained change in seizure frequency
• New or worsening CNS depression beyond expected levetiracetam effects
• Behavioral changes (levetiracetam can cause irritability, mood changes) 2

This recommendation is based on general principles of polypharmacy management, not specific evidence for this drug combination. Consultation with both neurology and infectious disease specialists is strongly advised when managing patients requiring both medications.